Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Genetics

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Objective To compare the predictive accuracy of β-amyloid (Aβ)1-42 and total tau in CSF, hippocampal volume (HCV), and APOE genotype for Alzheimer disease (AD)-type dementia in subjects with amnestic mild cognitive impairment (aMCI) and nonamnestic mild cognitive impairment (naMCI). Methods We selected 399 subjects with aMCI and 226 subjects with naMCI from a multicenter memory clinic-based cohort. We measured CSF Aβ1-42 and tau by ELISA (n = 231), HCV on MRI (n = 388), and APOE ε4 (n = 523). Follow-up was performed annually up to 5 years. Outcome measures were progression to AD-type dementia and cognitive decline. Results At least 1 follow-up was available for 538 subjects (86%). One hundred thirty-two subjects with aMCI (38%) and 39 subjects with naMCI (20%) progressed to AD-type dementia after an average follow-up of 2.5 years. CSF Aβ1-42, tau, Aβ1-42/tau ratio, HCV, and APOE ε4 predicted AD-type dementia in each MCI subgroup with the same overall diagnostic accuracy. However, CSF Aβ1-42 concentration was higher and hippocampal atrophy less severe in subjects with naMCI compared with aMCI. This reduced the sensitivity but increased the specificity of these markers for AD-type dementia in subjects with naMCI. Conclusions AD biomarkers are useful to predict AD-type dementia in subjects with aMCI and naMCI. However, biomarkers might not be as sensitive for early diagnosis of AD in naMCI compared with aMCI. This may have implications for clinical implementation of the National Institute on Aging and Alzheimer's Association criteria.

What this study adds

Evidence grade: Moderate

The record lists 231 participants. This supports using biomarkers to predict dementia but does not provide a treatment or cure.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Vos, S. J., van Rossum, I. A., Verhey, F., Knol, D. L., Soininen, H., Wahlund, L. O., et al. (2013). Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology. https://doi.org/10.1212/wnl.0b013e318288690c

Vancouver

Vos SJ, van Rossum IA, Verhey F, Knol DL, Soininen H, Wahlund LO, et al. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology. 2013. doi:10.1212/wnl.0b013e318288690c. PMID: 23446677.

BibTeX

@article{vos2013-23446677,
  author  = {Vos, S. J. and van Rossum, I. A. and Verhey, F. and Knol, D. L. and Soininen, H. and Wahlund, L. O. and Hampel, H. and Tsolaki, M. and others},
  title   = {{Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI}},
  journal = {Neurology},
  year    = {2013},
  doi     = {10.1212/wnl.0b013e318288690c},
  pmid    = {23446677},
  url     = {https://doi.org/10.1212/wnl.0b013e318288690c}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In this memory clinic cohort, CSF amyloid-beta1-42, tau, the amyloid-beta1-42/tau ratio, hippocampal volume, and APOE epsilon4 predicted progression to Alzheimer's-type dementia in both amnestic and nonamnestic mild cognitive impairment, though the markers were less sensitive in the nonamnestic group. This supports using biomarkers to predict dementia but does not provide a treatment or cure.

Study details

How this study scored 57/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 2 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 57 of 100.57 of 100 points earned43 not earned

Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Neurology)
Journal's citation record 4 / 4 Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2013 — within 20 year(s) of the newest study here
Sample size 2 / 4 231 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 133 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 8.9 citations a year over 15 year(s) since 2013
Impact for its field and year 4 / 6 Cited 10.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 8 other studies in this library
Still being cited 2 / 4 Cited 20 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Pieter Jelle Visser: h-index 90 (OpenAlex, whole career)
Institution's track record 2 / 3 Imperial College London: institution h-index 1,744 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 7 institution(s) in 5 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 23446677)
Free to read 0 / 2 Behind a paywall — scores zero
Total 57 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.

Later studies that cite this one

8 studies in the alzhub library list this one in their references.

Related studies in Genetics from nearby years

Also in Genetics

198 studies in the library are filed under Genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Genetics hub.

Similar studies

More on Genetics

See all studies in Genetics →